Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

138.61USD
17 May 2019
Change (% chg)

$0.40 (+0.29%)
Prev Close
$138.21
Open
$137.09
Day's High
$139.01
Day's Low
$136.86
Volume
2,010,284
Avg. Vol
2,030,524
52-wk High
$148.97
52-wk Low
$118.62

Latest Key Developments (Source: Significant Developments)

Ethicon Recalls Circular Staplers For Insufficient Firing, Failure To Completely Form Staples
Friday, 17 May 2019 

May 17 (Reuters) - FDA::ETHICON RECALLS CIRCULAR STAPLERS FOR INSUFFICIENT FIRING AND FAILURE TO COMPLETELY FORM STAPLES.U.S. FDA SAYS FDA HAS IDENTIFIED ETHICON'S RECALL OF CIRCULAR STAPLERS AS A CLASS I RECALL.FDA SAYS ETHICON CONFIRMED SERIOUS INJURIES TO TWO PATIENTS.U.S. FDA SAYS CIRCULAR STAPLER DEVICES RECALLED IN THE U.S. ARE 92,496 UNITS.U.S. FDA SAYS ETHICON CONFIRMED UNCUT WASHERS IN STAPLER & MALFORMED STAPLES OCCUR WITH THEIR INTRALUMINAL CIRCULAR STAPLERS DUE TO INSUFFICIENT FIRING.FDA SAYS RECALLED PRODUCTS INCLUDED ENDO-SURGERY CURVED INTRALUMINAL STAPLER WITH ADJUSTABLE HEIGHT STAPLES.FDA SAYS RECALLED PRODUCTS INCLUDED ENDO-SURGERY ENDOSCOPIC CURVED INTRALUMINAL STAPLER WITH ADJUSTABLE HEIGHT STAPLES.  Full Article

Geron Provides Imetelstat Program Update
Thursday, 16 May 2019 

May 16 (Reuters) - Geron Corp ::GERON PROVIDES IMETELSTAT PROGRAM UPDATE.GERON CORP - AS OF MAY 14, 2019, GERON ASSUMED IMETELSTAT IND SPONSORSHIP FROM JANSSEN.GERON CORP - PROCEEDING WITH START-UP ACTIVITIES FOR PHASE 3 PORTION OF IMERGE.GERON CORP - CONTINUES TO EXPECT PHASE 3 PORTION OF IMERGE TO BE OPEN FOR SCREENING AND ENROLLMENT BY MID-YEAR.GERON CORP - EXPECTS TO COMPLETE TRANSITION OF IMETELSTAT PROGRAM BY END OF Q3 OF 2019.GERON CORP - RE-ESTABLISHING ITS DRUG MANUFACTURING SUPPLY CHAIN AND EXPECTS TO HAVE ENGAGED ALL NECESSARY CONTRACT MANUFACTURING VENDORS BY END OF Q3.GERON CORP - REVISING OBJECTIVE TO COMMUNICATE DECISION REGARDING LATE-STAGE DEVELOPMENT IN RELAPSED/REFRACTORY MYELOFIBROSIS (MF) BY END OF Q3.GERON CORP - NOW PLANS TO CONDUCT AN END OF PHASE 2 (EOP2) MEETING FOR RELAPSED/REFRACTORY MYELOFIBROSIS WITH FDA BY END OF Q1 OF 2020.GERON CORP - INCREASED 2019 TOTAL OPERATING EXPENSE GUIDANCE TO A RANGE FROM $80 TO $85 MILLION.GERON CORP - AS OF MAY 15, 2019, CO HAS 31 EMPLOYEES, AND NOW PLANS TO GROW TO A TOTAL OF APPROXIMATELY 45 TO 50 EMPLOYEES BY YEAR-END 2019.GERON -2019 OPERATING EXPENSE OUTLOOK RISE PRIMARILY DUE TO ADDITIONAL INVENTORIES PURCHASE OF DRUG SUBSTANCE, DRUG PRODUCT, RAW MATERIALS FOR IMETELSTAT FROM JANSSEN.GERON - 2019 OPERATING EXPENSE OUTLOOK RISE ALSO DUE TO EXPECTED HIGHER CLINICAL OPERATIONAL COSTS OF ABOUT $5 MILLION.  Full Article

J&J Expects Pharma Business Will Realize Compounded Annual Growth Rate Of At Least 5% Between Now And 2023
Thursday, 16 May 2019 

May 15 (Reuters) - Johnson & Johnson ::J&J EXECUTIVE SEES SALES POTENTIAL OF MORE THAN $1 BILLION A YEAR FOR EACH DRUG CO EXPECTS TO FILE MARKETING APPLICATIONS FOR BY 2023.J&J EXPECTS PHARMA BUSINESS WILL REALIZE COMPOUNDED ANNUAL GROWTH RATE OF AT LEAST 5% BETWEEN NOW AND 2023.  Full Article

Johnson & Johnson Plans To File For Regulatory Approval Or Launch At Least 10 New Drugs Between 2019 And 2023
Wednesday, 15 May 2019 

May 15 (Reuters) - Johnson & Johnson ::JOHNSON & JOHNSON OUTLINES STRATEGY TO DELIVER ABOVE-MARKET GROWTH AT 2019 PHARMACEUTICAL BUSINESS REVIEW.J&J - PLANS TO FILE FOR REGULATORY APPROVAL OR LAUNCH AT LEAST 10 NEW MEDICINES BETWEEN 2019 AND 2023.J&J - PLANS TO FILE FOR REGULATORY APPROVAL OR LAUNCH AT LEAST 10 NEW MEDICINES BETWEEN 2019 AND 2023.J&J - PLANS TO MAXIMIZE POTENTIAL OF LEADING BRANDS BY FILING MORE THAN 40 LINE EXTENSIONS FOR REGULATORY APPROVAL THROUGH 2023.J&J - COMPANY IS ALSO COMMITTED TO DELIVERING A COMPETITIVE AND INCREASING DIVIDEND.J&J - COMMITTED TO DELIVERING A COMPETITIVE AND INCREASING DIVIDEND, HAVING PAID $9.5 BILLION IN DIVIDENDS TO SHAREHOLDERS IN 2018.J&J - JANSSEN ANTICIPATES FILING FOR REGULATORY APPROVAL OF MORE THAN 40 LINE EXTENSIONS THROUGH 2023.J&J - TO CONTINUE TO DEPLOY CAPITAL TO VALUE-CREATING ACQUISITIONS WITH MORE THAN $5 BILLION INVESTED IN ACQUISITIONS ACROSS CO IN RECENT MONTHS.J&J - COMPLETED MORE THAN ONE-THIRD OF ITS $5 BILLION SHARE REPURCHASES AUTHORIZATION ANNOUNCED LAST YEAR AS OF MARCH 2019.J&J - IN TUESDAY'S MEETING, ADDITIONAL MEDICINES WILL BE DISCUSSED THAT HAVE POTENTIAL TO FILE/LAUNCH BY 2023, INCLUDING 4 THAT ARE NEW TO PIPELINE.  Full Article

Protagonist Says Initial Results From Phase 1 Study Of PN-943 Expected In Q2
Wednesday, 8 May 2019 

May 8 (Reuters) - Protagonist Therapeutics Inc ::PROTAGONIST THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.PROTAGONIST THERAPEUTICS- PTG-200 COLLABORATION AGREEMENT WITH JANSSEN BIOTECH EXPANDED TO INCLUDE SECOND GENERATION ORAL IL-23 RECEPTOR ANTAGONISTS.PROTAGONIST THERAPEUTICS INC - EXPANDED PTG-200 AGREEMENT TRIGGERS $25 MILLION MILESTONE PAYMENT TO PROTAGONIST.PROTAGONIST THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.58.PROTAGONIST THERAPEUTICS INC - QTRLY LICENSE AND COLLABORATION REVENUE WAS $1.6 MILLION COMPARED TO $10.8 MILLION FOR SAME PERIOD OF 2018.PROTAGONIST THERAPEUTICS INC - EXPECTS TO HAVE SUFFICIENT FINANCIAL RESOURCES TO FUND OPERATIONS TO END OF 2020.PROTAGONIST THERAPEUTICS INC - PROTAGONIST ENDED Q1 OF 2019 WITH $112.5 MILLION IN CASH, CASH EQUIVALENTS AND INVESTMENTS.PROTAGONIST THERAPEUTICS INC - INITIAL RESULTS FROM PHASE 1 STUDY OF PN-943 EXPECTED IN Q2 OF 2019.PROTAGONIST THERAPEUTICS -PRELIMINARY RESULTS FROM PHASE 2 TRANSCEND STUDY OF PTG-300 FOR TREATMENT OF BETA THALASSEMIA EXPECTED IN H219.  Full Article

Protagonist Therapeutics Inc Protagonist Receives $25 Mln Payment
Wednesday, 8 May 2019 

May 8 (Reuters) - Protagonist Therapeutics Inc ::PROTAGONIST THERAPEUTICS INC - PROTAGONIST RECEIVES A $25 MILLION PAYMENT.PROTAGONIST THERAPEUTICS INC - JANSSEN TO ADVANCE PTG-200 FORWARD TO PHASE 2 CROHN'S STUDY.PROTAGONIST THERAPEUTICS INC - PROTAGONIST IS NOW ELIGIBLE FOR TOTAL MILESTONES IN EXCESS OF $1 BILLION AND TIERED ROYALTY PAYMENTS ON NET SALES.PROTAGONIST THERAPEUTICS EXPANDS PTG-200 COLLABORATION AGREEMENT WITH JANSSEN TO INCLUDE SECOND GENERATION ORAL IL-23 RECEPTOR ANTAGONISTS.PROTAGONIST THERAPEUTICS INC - JANSSEN WILL PAY CERTAIN COSTS AND MILESTONES RELATED TO ADVANCING PRE-CLINICAL CANDIDATES THROUGH PHASE 1 STUDIES.  Full Article

J&J Pays About $1 Bln To Resolve Pinnacle-Hip Suits - Bloomberg, Citing Sources
Tuesday, 7 May 2019 

May 7 (Reuters) - :J&J PAYS ABOUT $1 BILLION TO RESOLVE PINNACLE-HIP SUITS - BLOOMBERG, CITING SOURCES.  Full Article

J&J Says As Of March 31, There Were About 14,200 Plaintiffs In Body Powders Containing Talc Lawsuits
Thursday, 2 May 2019 

May 1 (Reuters) - Johnson & Johnson ::J&J - AS OF MARCH 31, IN U.S. THERE WERE ABOUT 1,700 PLAINTIFFS WITH DIRECT CLAIMS IN PENDING LAWSUITS REGARDING INJURIES ALLEGEDLY DUE TO DEPUY ASR XL ACETABULAR SYSTEM AND DEPUY ASR HIP RESURFACING SYSTEM.J&J - AS OF MARCH 31, IN U.S. THERE WERE ABOUT 10,500 PLAINTIFFS WITH DIRECT CLAIMS IN PENDING LAWSUITS WITH RESPECT TO PINNACLE ACETABULAR CUP SYSTEM.J&J - AS OF MARCH 31, IN U.S. THERE WERE ABOUT 14,200 PLAINTIFFS WITH CLAIMS IN PENDING LAWSUITS WITH RESPECT TO BODY POWDERS CONTAINING TALC.J&J - CO HAD REPORTED THERE WERE ABOUT 13,000 PLAINTIFFS AS OF DEC 30 IN U.S. WITH CLAIMS IN PENDING LAWSUITS WITH RESPECT TO BODY POWDERS CONTAINING TALC.J&J - AS OF MARCH 31, IN U.S. THERE WERE ABOUT 29,500 PLAINTIFFS IN LAWSUITS WITH RESPECT TO PELVIC MESHES & 27,300 WITH RESPECT TO XARELTO.  Full Article

Janssen Says Submission Of NDA To FDA For Two-Drug Regimen Of Rilpivirine & Cabotegravir For Treatment Of HIV
Tuesday, 30 Apr 2019 

April 29 (Reuters) - Johnson & Johnson ::JANSSEN - SUBMISSION OF NEW DRUG APPLICATION TO FDA FOR FIRST MONTHLY, INJECTABLE, TWO-DRUG REGIMEN OF RILPIVIRINE & CABOTEGRAVIR FOR TREATMENT OF HIV.JANSSEN - SUBMISSION IS BASED ON ATLAS & FLAIR PIVOTAL PHASE 3 STUDIES THAT INCLUDED MORE THAN 1,100 PATIENTS FROM 16 COUNTRIES.JANSSEN - NOVEL REGIMEN IS BEING CO-DEVELOPED AS PART OF COLLABORATION BETWEEN JANSSEN & VIIV HEALTHCARE.JANSSEN - CO, VIIV PLAN TO SUBMIT REGULATORY APPLICATIONS FOR 2-DRUG REGIMEN OF RILPIVIRINE, CABOTEGRAVIR TO EMA, HEALTH CANADA IN COMING MONTHS.  Full Article

Janssen Submits Application To U.S. FDA Seeking Approval Of Erleada
Tuesday, 30 Apr 2019 

April 29 (Reuters) - Johnson & Johnson ::JANSSEN SUBMITS APPLICATION TO U.S. FDA SEEKING APPROVAL OF ERLEADA® (APALUTAMIDE) FOR PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER.JANSSEN SUBMITS APPLICATION TO U.S. FDA SEEKING APPROVAL OF ERLEADA® (APALUTAMIDE) FOR PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER.JANSSEN SAYS SNDA IS BEING REVIEWED BY FDA THROUGH REAL-TIME ONCOLOGY REVIEW (RTOR) PROGRAM.  Full Article

Photo

Modi’s jobs deficit: J&J’s largest India plant idle three years after completion

PENJERLA/NEW DELHI, India It was supposed to be Johnson & Johnson's biggest manufacturing plant in India. It was to eventually employ at least 1,500 people and help bring development to a rural area near Hyderabad in southern India.